Valproic acid serum levels and protection against kindled amygdaloid scizures in the rat

Timothy E Albertson; S. L. Peterson; L. G. Stark; R. C. Baselt

doi:10.1016/0028-3908(81)90050-2

Valproic acid serum levels and protection against kindled amygdaloid scizures in the rat

Timothy E Albertson, S. L. Peterson, L. G. Stark, R. C. Baselt

Pulmonary, Critical Care, and Sleep Medicine

Research output: Contribution to journal › Article

12 Scopus citations

Abstract

Valproic acid has been reported to be very effective against kindled amygdaloid Scizures in several species. In this study, the anticonvulsant effectiveness of valproic acid against kindled amygdaloid Scizures was studied in a systematic, multiple-dose evaluation in rats. A correlation at 30 min. between the degree of Scizure protection and increased serum levels of valproic acid was seen. At 30 min., the fifty percent effective dose (ED₅₀) was found to be 200 mg/kg. Additionally, the fifty percent effective serum level (ESL₅₀) was estimated to be 500 mg/L.

Original language	English (US)
Pages (from-to)	95-97
Number of pages	3
Journal	Neuropharmacology
Volume	20
Issue number	1
DOIs	https://doi.org/10.1016/0028-3908(81)90050-2
State	Published - 1981

Fingerprint

ASJC Scopus subject areas

Cellular and Molecular Neuroscience
Drug Discovery
Pharmacology

Cite this

Albertson, T. E., Peterson, S. L., Stark, L. G., & Baselt, R. C. (1981). Valproic acid serum levels and protection against kindled amygdaloid scizures in the rat. Neuropharmacology, 20(1), 95-97. https://doi.org/10.1016/0028-3908(81)90050-2

@article{848ac77165844013bfdaf92f6aeacbaa,

title = "Valproic acid serum levels and protection against kindled amygdaloid scizures in the rat",

abstract = "Valproic acid has been reported to be very effective against kindled amygdaloid Scizures in several species. In this study, the anticonvulsant effectiveness of valproic acid against kindled amygdaloid Scizures was studied in a systematic, multiple-dose evaluation in rats. A correlation at 30 min. between the degree of Scizure protection and increased serum levels of valproic acid was seen. At 30 min., the fifty percent effective dose (ED50) was found to be 200 mg/kg. Additionally, the fifty percent effective serum level (ESL50) was estimated to be 500 mg/L.",

author = "Albertson, {Timothy E} and Peterson, {S. L.} and Stark, {L. G.} and Baselt, {R. C.}",

year = "1981",

doi = "10.1016/0028-3908(81)90050-2",

language = "English (US)",

volume = "20",

pages = "95--97",

journal = "Neuropharmacology",

issn = "0028-3908",

publisher = "Elsevier Limited",

number = "1",

}

TY - JOUR

T1 - Valproic acid serum levels and protection against kindled amygdaloid scizures in the rat

AU - Albertson, Timothy E

AU - Peterson, S. L.

AU - Stark, L. G.

AU - Baselt, R. C.

PY - 1981

Y1 - 1981

N2 - Valproic acid has been reported to be very effective against kindled amygdaloid Scizures in several species. In this study, the anticonvulsant effectiveness of valproic acid against kindled amygdaloid Scizures was studied in a systematic, multiple-dose evaluation in rats. A correlation at 30 min. between the degree of Scizure protection and increased serum levels of valproic acid was seen. At 30 min., the fifty percent effective dose (ED50) was found to be 200 mg/kg. Additionally, the fifty percent effective serum level (ESL50) was estimated to be 500 mg/L.

AB - Valproic acid has been reported to be very effective against kindled amygdaloid Scizures in several species. In this study, the anticonvulsant effectiveness of valproic acid against kindled amygdaloid Scizures was studied in a systematic, multiple-dose evaluation in rats. A correlation at 30 min. between the degree of Scizure protection and increased serum levels of valproic acid was seen. At 30 min., the fifty percent effective dose (ED50) was found to be 200 mg/kg. Additionally, the fifty percent effective serum level (ESL50) was estimated to be 500 mg/L.

UR - http://www.scopus.com/inward/record.url?scp=0019352492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019352492&partnerID=8YFLogxK

U2 - 10.1016/0028-3908(81)90050-2

DO - 10.1016/0028-3908(81)90050-2

M3 - Article

C2 - 6783975

AN - SCOPUS:0019352492

VL - 20

SP - 95

EP - 97

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 1

ER -

Access to Document

10.1016/0028-3908(81)90050-2